Sequence-Specific Pharmacokinetic and Pharmacodynamic Phase I/Ib Study of Olaparib Tablets and Carboplatin in Women's Cancer
Jung Min Lee(Kyung Hee University), Elise C. Kohn(National Cancer Institute), Cody J. Peer(National Institutes of Health), Christina M. Annunziata(National Cancer Institute), Lori M. Minasian(National Cancer Institute), Tristan M. Sissung(National Institutes of Health), Andrew K.L. Goey(Roswell Park Comprehensive Cancer Center), Nicolas Gordon(National Institutes of Health), Victoria L. Chiou(Center for Cancer Research), Brigitte C. Widemann(National Cancer Institute), William D. Figg(National Cancer Institute), Lauren Amable(University of South Alabama), Robert F. Murphy(Center for Cancer Research), Minshu Yu(National Institutes of Health), Bernard W. Parker(Center for Cancer Research), Nicole Houston(Johns Hopkins University)
Cited by 59
Related Papers
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k
Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JAMA Oncology|2015|1k
Precisely printable and biocompatible silk fibroin bioink for digital light processing 3D printing
|Nature Communications|2018|964